Enanta Pharmaceuticals (ENTA) Net Cash Flow (2012 - 2026)

Enanta Pharmaceuticals' Net Cash Flow history runs 15 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• Quarterly Net Cash Flow rose 89.86% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.3 million (down 542.24% YoY) and the FY2025 annual result came in at -$5.5 million, up 88.49% from the prior year.
• Net Cash Flow was -$2.5 million for Q1 2026 at Enanta Pharmaceuticals, down from $5.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $47.1 million in Q4 2024 and bottomed at -$58.1 million in Q1 2022.
• A 5-year average of -$3.6 million and a median of -$2.5 million in 2026 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 337.52% in 2023, while the deepest fall reached 2466.63% in 2023.
• Enanta Pharmaceuticals' Net Cash Flow stood at -$1.8 million in 2022, then slumped by 2466.63% to -$45.5 million in 2023, then surged by 203.65% to $47.1 million in 2024, then plunged by 89.09% to $5.1 million in 2025, then tumbled by 148.82% to -$2.5 million in 2026.
• Business Quant data shows ENTA's Net Cash Flow at -$2.5 million in Q1 2026, $5.1 million in Q4 2025, and -$12.5 million in Q3 2025.